Safety profile of ajmaline testing in Brugada syndrome: influence of SCNA5 mutations
N Drapier, J Gourraud, D Therasse, P Petit, V Cotard, A Thollet, B Pierre, N Behar, J Mansourati, F Sacher, G Clerici, V Probst · 2026
Read Safety profile of ajmaline testing in Brugada syndrome: influence of SCNA5 mutations by N Drapier, J Gourraud, D Therasse, P Petit, V Cotard, A Thollet, B Pierre, N Behar, J Mansourati, F Sacher, G Clerici, V Probst (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13300393.txt.
Description
N Drapier and colleagues examine the safety of ajmaline testing in Brugada syndrome in a 2026 study, asking whether mutations in the SCN5A sodium channel gene raise the danger. Drug challenge testing unmasks the syndrome's hidden electrocardiogram pattern but can provoke serious rhythms. The retrospective series covered 3,192 patients tested with ajmaline or flecainide at their centers between 1994 and 2025, with genetic results and complications recorded.
Sustained fast ventricular rhythms were rare overall yet clearly concentrated among mutation carriers. Ventricular fibrillation occurred in four patients, split between the carrier and uncertain-variant groups, with none among non-carriers. Adjusted analysis left mutation status, a longer PR interval, and a wider QRS pattern as independent predictors of complications. The authors conclude that carriers need heightened caution, while non-carriers face an extremely low risk during testing.
Catalog record
| CREATOR | N Drapier, J Gourraud, D Therasse, P Petit, V Cotard, A Thollet, B Pierre, N Behar, J Mansourati, F Sacher, G Clerici, V Probst |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |